FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087733982> ?p ?o ?g. }

• W3087733982 endingPage "102996" @default.
• W3087733982 startingPage "102996" @default.
• W3087733982 abstract "BackgroundPertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found to have synergistic efficacy when combined with trastuzumab, it remains to be seen whether a more potent synergistic efficacy partner exists for trastuzumab.MethodsA trastuzumab-based functional assay was used to screen anti-HER2 antibodies harboring trastuzumab-synergistic antitumor activity. The lead candidate 5G9, in combination with trastuzumab, was further characterized for its bioactivities in cell proliferation, cell apoptosis, antigen-antibody endocytosis and HER2-mediated cell signaling pathway blocking. Finally, animal models were used to evaluate the in vivo synergistic antitumor efficacy of 5G9 in combination with trastuzumab.FindingsCompared to pertuzumab, 5G9 demonstrated more potent synergistic cell growth inhibitory activity when combined with trastuzumab (85% vs. 55%, P<0.001). In addition, 5G9 exhibited a higher internalization rate than pertuzumab (20% vs. 9%, P<0.05), and was able to further synergize with trastuzumab to promote antigen-antibody endocytosis. The internalization rate of the combination of 5G9 and trastuzumab was higher than that of pertuzumab and trastuzumab (35% vs. 14%, P<0.001). In vivo animal studies demonstrated that 5G9 in combination with trastuzumab showed more potent synergistic antitumor efficacy than the combination of pertuzumab and trastuzumab.Interpretation5G9, together with trastuzumab, may provide a potential opportunity for more efficacious treatment of HER2-positive cancers.FundingNational Natural Science Foundation of China; State Key Laboratory of Analytical Chemistry for Life Science." @default.
• W3087733982 created "2020-09-25" @default.
• W3087733982 creator A5007510363 @default.
• W3087733982 creator A5013173865 @default.
• W3087733982 creator A5014645131 @default.
• W3087733982 creator A5021695031 @default.
• W3087733982 creator A5035591504 @default.
• W3087733982 creator A5036985869 @default.
• W3087733982 creator A5076612556 @default.
• W3087733982 creator A5087092985 @default.
• W3087733982 creator A5087137290 @default.
• W3087733982 date "2020-10-01" @default.
• W3087733982 modified "2023-10-13" @default.
• W3087733982 title "A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity" @default.
• W3087733982 cites W1968961303 @default.
• W3087733982 cites W1969602144 @default.
• W3087733982 cites W1992815045 @default.
• W3087733982 cites W1997681258 @default.
• W3087733982 cites W2002387745 @default.
• W3087733982 cites W2028127376 @default.
• W3087733982 cites W2029806600 @default.
• W3087733982 cites W2034975420 @default.
• W3087733982 cites W2036752075 @default.
• W3087733982 cites W2071940088 @default.
• W3087733982 cites W2076954124 @default.
• W3087733982 cites W2095156669 @default.
• W3087733982 cites W2104239861 @default.
• W3087733982 cites W2111628999 @default.
• W3087733982 cites W2113479218 @default.
• W3087733982 cites W2119494303 @default.
• W3087733982 cites W2122197137 @default.
• W3087733982 cites W2122983196 @default.
• W3087733982 cites W2123896705 @default.
• W3087733982 cites W2137950260 @default.
• W3087733982 cites W2139135964 @default.
• W3087733982 cites W2141393790 @default.
• W3087733982 cites W2143352606 @default.
• W3087733982 cites W2159967578 @default.
• W3087733982 cites W2164009002 @default.
• W3087733982 cites W2165003903 @default.
• W3087733982 cites W2166199281 @default.
• W3087733982 cites W2169782526 @default.
• W3087733982 cites W2171584014 @default.
• W3087733982 cites W2233888390 @default.
• W3087733982 cites W2460150844 @default.
• W3087733982 cites W2551315898 @default.
• W3087733982 cites W2577651608 @default.
• W3087733982 cites W2901009857 @default.
• W3087733982 cites W2904779531 @default.
• W3087733982 doi "https://doi.org/10.1016/j.ebiom.2020.102996" @default.
• W3087733982 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7501074" @default.
• W3087733982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32950002" @default.
• W3087733982 hasPublicationYear "2020" @default.
• W3087733982 type Work @default.
• W3087733982 sameAs 3087733982 @default.
• W3087733982 citedByCount "2" @default.
• W3087733982 countsByYear W30877339822021 @default.
• W3087733982 crossrefType "journal-article" @default.
• W3087733982 hasAuthorship W3087733982A5007510363 @default.
• W3087733982 hasAuthorship W3087733982A5013173865 @default.
• W3087733982 hasAuthorship W3087733982A5014645131 @default.
• W3087733982 hasAuthorship W3087733982A5021695031 @default.
• W3087733982 hasAuthorship W3087733982A5035591504 @default.
• W3087733982 hasAuthorship W3087733982A5036985869 @default.
• W3087733982 hasAuthorship W3087733982A5076612556 @default.
• W3087733982 hasAuthorship W3087733982A5087092985 @default.
• W3087733982 hasAuthorship W3087733982A5087137290 @default.
• W3087733982 hasBestOaLocation W30877339821 @default.
• W3087733982 hasConcept C121608353 @default.
• W3087733982 hasConcept C126322002 @default.
• W3087733982 hasConcept C139770010 @default.
• W3087733982 hasConcept C150903083 @default.
• W3087733982 hasConcept C159654299 @default.
• W3087733982 hasConcept C170493617 @default.
• W3087733982 hasConcept C203014093 @default.
• W3087733982 hasConcept C207001950 @default.
• W3087733982 hasConcept C2779786085 @default.
• W3087733982 hasConcept C2781164504 @default.
• W3087733982 hasConcept C502942594 @default.
• W3087733982 hasConcept C530470458 @default.
• W3087733982 hasConcept C71924100 @default.
• W3087733982 hasConcept C86803240 @default.
• W3087733982 hasConcept C98274493 @default.
• W3087733982 hasConceptScore W3087733982C121608353 @default.
• W3087733982 hasConceptScore W3087733982C126322002 @default.
• W3087733982 hasConceptScore W3087733982C139770010 @default.
• W3087733982 hasConceptScore W3087733982C150903083 @default.
• W3087733982 hasConceptScore W3087733982C159654299 @default.
• W3087733982 hasConceptScore W3087733982C170493617 @default.
• W3087733982 hasConceptScore W3087733982C203014093 @default.
• W3087733982 hasConceptScore W3087733982C207001950 @default.
• W3087733982 hasConceptScore W3087733982C2779786085 @default.
• W3087733982 hasConceptScore W3087733982C2781164504 @default.
• W3087733982 hasConceptScore W3087733982C502942594 @default.
• W3087733982 hasConceptScore W3087733982C530470458 @default.
• W3087733982 hasConceptScore W3087733982C71924100 @default.
• W3087733982 hasConceptScore W3087733982C86803240 @default.
• W3087733982 hasConceptScore W3087733982C98274493 @default.

• next